Biotinylated Human IGSF8 Protein, Avitag?,His Tag (MALS verified)
分子別名（Synonym）
IgSF8,CD316,CD81P3,EWI-2,EWI2,KCT-4,LIR-D1,PGRL
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human IGSF8 Protein, Avitag,His Tag (IG8-H82Q3) is expressed from human 293 cells (HEK293). It contains AA Arg 28 - Thr 579 (Accession # Q969P0).
Predicted N-terminus: Gly
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries an Avi tag (Avitag?) at the N-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 62.1 kDa. The protein migrates as 65-70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
IGSF8 (Immunoglobulin superfamily member 8) is a member the EWI subfamily of the immunoglobulin protein superfamily, also known as EWI-2, KCT-4, LIR-D1, and PGRL. It interacts with the tetraspanins CD81 and CD9 and may regulate their role in certain cellular functions including cell migration and viral infection. IGSF8 suppresses T-cell mobility coordinately with CD81, associates with CD82 to suppress prostate cancer cell migration, regulates epidermoid cell reaggregation and motility on laminin-5 with CD9 and CD81 as key linkers. It may also play a role on integrin-dependent morphology and motility functions, and may participate in the regulation of neurite outgrowth and maintenance of the neural network in the adult brain. Recent research indicates that IGSF8 is highly expressed on malignant cells with antigen presentation defects, and it interacts with NK receptors to suppress NK cell cytotoxicity.
關(guān)鍵字： IGSF8;IGSF8蛋白;IGSF8重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。